查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1607977

骨髓惡性腫瘤市場：按類型、治療、診斷、最終用戶分類 - 全球預測 2025-2030

Hematological Malignancies Market by Types (Leukemia, Lymphoma, Multiple Myeloma), Treatment (Bone Marrow Transplantation, Chemotherapy, Chimeric Antigen Receptor (Car) T Cell Therapy), Diagnosis, End-Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

骨髓惡性腫瘤市場2023年估值為153.3億美元，預計到2024年將達到168.4億美元，複合年成長率為9.92%，到2030年將達到297.3億美元。

骨髓惡性腫瘤包括多種與血液相關的癌症，包括白血病、淋巴瘤和多發性骨髓瘤。其範圍包括闡明疾病機制、改進診斷方法和開發新治療方法。這些癌症的盛行率不斷上升以及分子生物學和基因組學的進步凸顯了對創新治療策略和準確診斷的需求。最終用途涵蓋製藥、生物技術和診斷領域，包括醫院、研究機構和專科診所。該市場受到癌症研究資金增加、個人化醫療進步以及標靶治療研究和開發等因素的支持。機會包括 CAR-T 細胞療法的出現、基於 RNA 的治療方法的擴展以及有望實現個人化治療方法的次世代定序的進步。對毒性更低、更有效的治療方法的需求也推動了免疫療法和聯合治療的研究。然而，高昂的治療成本、嚴格的監管環境以及臨床試驗的複雜性等挑戰構成了重大障礙。我們還需要解決與現有療法相關的抗藥性和副作用。策略建議包括投資於早期研究夥伴關係以及促進與學術機構的合作以加速創新。基因編輯技術（如 CRISPR）和液態切片等領域的開拓有可能進一步徹底改變診斷和監測。市場競爭依然激烈，研發不斷將經濟高效且可擴展的解決方案推向前線。透過專注於改善患者資料整合和數位健康干預措施，我們可以改善患者治療結果並簡化臨床試驗流程。市場的本質是動態的，不斷轉向基於價值的護理並強調整體患者管理。為了保持競爭優勢，公司必須優先考慮適應性，投資新技術，並不斷回應醫療保健提供者和患者不斷變化的需求。

主要市場統計
基準年[2023] 153.3億美元
預計年份 [2024] 168.4億美元
預測年份 [2030] 297.3億美元
複合年成長率（%） 9.92%

市場動態：快速發展的骨髓惡性腫瘤市場的關鍵市場洞察

供需的動態交互作用正在改變骨髓惡性腫瘤市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 血癌患者增加
    • 提高對早期診斷可能性的認知
    • 有利的法規環境和政府對治療的支持
  • 市場限制因素
    • 缺乏與骨髓惡性腫瘤治療相關的認知和高昂的費用
  • 市場機會
    • 增加對開發先進骨髓惡性腫瘤的投資
    • 骨髓惡性腫瘤治療新藥核准上市數量快速增加
  • 市場挑戰
    • 骨髓惡性腫瘤治療藥物缺乏熟練專業人員和副作用

波特五力：駕馭骨髓惡性腫瘤市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解骨髓惡性腫瘤市場的外部影響

外部宏觀環境因素在塑造骨髓惡性腫瘤市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解骨髓惡性腫瘤市場的競爭格局

骨髓惡性腫瘤市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來發現自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣骨髓惡性腫瘤市場供應商的績效評估

FPNV 定位矩陣是評估骨髓惡性腫瘤市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了骨髓惡性腫瘤市場的成功之路

骨髓惡性腫瘤市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 血癌發生率增加
      • 提高對早期診斷可能性的認知
      • 有利的法規環境和政府對治療方法的支持
    • 抑制因素
      • 對骨髓惡性腫瘤治療缺乏認知且費用龐大
    • 機會
      • 增加對開發先進骨髓惡性腫瘤的投資
      • 新藥核准上市數量快速增加
    • 任務
      • 缺乏熟練的專業人員和骨髓惡性腫瘤治療的副作用
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章骨髓惡性腫瘤市場：依類型

  • 白血病
  • 淋巴瘤
  • 多發性骨髓瘤

第7章依治療分類的骨髓惡性腫瘤市場

  • 骨髓移植
  • 化療
  • 嵌合體抗原受體 (Car) T 細胞療法
  • 免疫療法
  • 標靶治療

第8章骨髓惡性腫瘤診斷市場

  • 切片檢查
  • 驗血
  • 影像檢查

第9章骨髓惡性腫瘤市場：依最終用戶分類

  • 居家護理
  • 醫院
  • 專科診所

第10章美洲骨髓惡性腫瘤市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太骨髓惡性腫瘤市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲/中東/非洲骨髓惡性腫瘤市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Adaptimmune Limited
  • Adcendo ApS
  • Amgen Inc.
  • Artiva Biotherapeutics, Inc.
  • Atara Biotherapeutics, Inc.
  • Bristol-Myers Squibb Company
  • Dren Bio, Inc.
  • F. Hoffmann-La Roche AG
  • Geron Corporation
  • GlaxoSmithKline PLC
  • Harpoon Therapeutics, Inc.
  • Immune-Onc Therapeutics, Inc.
  • Interius BioTherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Karyopharm Therapeutics Inc.
  • Kirilys Therapeutics, Inc.
  • Kymera Therapeutics
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • Moleculin Biotech, Inc.
  • NovalGen Ltd.
  • Novartis AG
  • Oncoternal
  • Pfizer Inc.
  • Prelude Therapeutics Incorporated
  • Reverie Labs Inc.
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • TG Therapeutics, Inc.
  • Tvardi Therapeutics, Inc.
Product Code: MRR-C002B1C994F0

The Hematological Malignancies Market was valued at USD 15.33 billion in 2023, expected to reach USD 16.84 billion in 2024, and is projected to grow at a CAGR of 9.92%, to USD 29.73 billion by 2030.

Hematological malignancies encompass a diverse group of blood-related cancers, including leukemia, lymphoma, and multiple myeloma. The scope involves understanding disease mechanisms, improving diagnostics, and developing novel therapies. The rising incidence of these cancers and advances in molecular biology and genomics underline the necessity of innovative therapeutic strategies and precise diagnostics. The application spans pharmaceuticals, biotechnology, and diagnostic sectors, with end-use across hospitals, research institutes, and specialty clinics. The market is buoyed by factors like increased funding for cancer research, advancements in personalized medicine, and the development of targeted therapies. Opportunities arise from the emergence of CAR-T cell therapies, expanding RNA-based treatments, and advancements in next-generation sequencing, which promise personalized treatment regimens. The demand for less toxic and more efficient treatments has also catalyzed research into immunotherapies and combination treatments. However, challenges such as high treatment costs, stringent regulatory landscapes, and the complexity of clinical trials pose significant hindrances. There's also a need to address drug resistance and the adverse effects associated with existing therapies. Strategic recommendations include investing in early-stage research partnerships and fostering collaboration with academic institutions to accelerate innovation. Exploring areas like gene editing technologies (e.g., CRISPR) and liquid biopsies could further revolutionize diagnostics and monitoring. The market remains highly competitive, with sustained R&D to bring cost-effective and scalable solutions to the forefront. Focused efforts on improving patient data integration and digital health interventions can enhance patient outcomes and streamline clinical trial processes. The nature of the market is dynamic, with ongoing shifts towards value-based care and emphasis on holistic patient management. To maintain competitive advantage, businesses should prioritize adaptability, invest in emerging technologies, and continuously address the evolving needs of healthcare providers and patients within the hematological malignancies landscape.

KEY MARKET STATISTICS
Base Year [2023] USD 15.33 billion
Estimated Year [2024] USD 16.84 billion
Forecast Year [2030] USD 29.73 billion
CAGR (%) 9.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hematological Malignancies Market

The Hematological Malignancies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of hematological cancer cases
    • Rising awareness about the possibility of early diagnosis
    • Favorable regulatory environment and government support for therapies
  • Market Restraints
    • Lack of awareness and huge cost associated with hematological malignancies treatment
  • Market Opportunities
    • Rising investment in the development of advanced hematological malignancies treatment
    • Surging drug approvals and launches of novel hematological malignancies drugs
  • Market Challenges
    • Dearth of skilled professionals and side effects of hematological malignancies therapies

Porter's Five Forces: A Strategic Tool for Navigating the Hematological Malignancies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hematological Malignancies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hematological Malignancies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hematological Malignancies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hematological Malignancies Market

A detailed market share analysis in the Hematological Malignancies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hematological Malignancies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hematological Malignancies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hematological Malignancies Market

A strategic analysis of the Hematological Malignancies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hematological Malignancies Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Limited, Adcendo ApS, Amgen Inc., Artiva Biotherapeutics, Inc., Atara Biotherapeutics, Inc., Bristol-Myers Squibb Company, Dren Bio, Inc., F. Hoffmann-La Roche AG, Geron Corporation, GlaxoSmithKline PLC, Harpoon Therapeutics, Inc., Immune-Onc Therapeutics, Inc., Interius BioTherapeutics, Inc., Johnson & Johnson Services, Inc., Karyopharm Therapeutics Inc., Kirilys Therapeutics, Inc., Kymera Therapeutics, MEI Pharma, Inc., Merck & Co., Inc., Moleculin Biotech, Inc., NovalGen Ltd., Novartis AG, Oncoternal, Pfizer Inc., Prelude Therapeutics Incorporated, Reverie Labs Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, TG Therapeutics, Inc., and Tvardi Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the Hematological Malignancies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Types, market is studied across Leukemia, Lymphoma, and Multiple Myeloma.
  • Based on Treatment, market is studied across Bone Marrow Transplantation, Chemotherapy, Chimeric Antigen Receptor (Car) T Cell Therapy, Immunotherapy, and Targeted Therapy.
  • Based on Diagnosis, market is studied across Biopsy, Blood Tests, and Imaging Tests.
  • Based on End-Users, market is studied across Homecare, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of hematological cancer cases
      • 5.1.1.2. Rising awareness about the possibility of early diagnosis
      • 5.1.1.3. Favorable regulatory environment and government support for therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness and huge cost associated with hematological malignancies treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising investment in the development of advanced hematological malignancies treatment
      • 5.1.3.2. Surging drug approvals and launches of novel hematological malignancies drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Dearth of skilled professionals and side effects of hematological malignancies therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hematological Malignancies Market, by Types

  • 6.1. Introduction
  • 6.2. Leukemia
  • 6.3. Lymphoma
  • 6.4. Multiple Myeloma

7. Hematological Malignancies Market, by Treatment

  • 7.1. Introduction
  • 7.2. Bone Marrow Transplantation
  • 7.3. Chemotherapy
  • 7.4. Chimeric Antigen Receptor (Car) T Cell Therapy
  • 7.5. Immunotherapy
  • 7.6. Targeted Therapy

8. Hematological Malignancies Market, by Diagnosis

  • 8.1. Introduction
  • 8.2. Biopsy
  • 8.3. Blood Tests
  • 8.4. Imaging Tests

9. Hematological Malignancies Market, by End-Users

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Hematological Malignancies Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Hematological Malignancies Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Hematological Malignancies Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Adaptimmune Limited
  • 3. Adcendo ApS
  • 4. Amgen Inc.
  • 5. Artiva Biotherapeutics, Inc.
  • 6. Atara Biotherapeutics, Inc.
  • 7. Bristol-Myers Squibb Company
  • 8. Dren Bio, Inc.
  • 9. F. Hoffmann-La Roche AG
  • 10. Geron Corporation
  • 11. GlaxoSmithKline PLC
  • 12. Harpoon Therapeutics, Inc.
  • 13. Immune-Onc Therapeutics, Inc.
  • 14. Interius BioTherapeutics, Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Karyopharm Therapeutics Inc.
  • 17. Kirilys Therapeutics, Inc.
  • 18. Kymera Therapeutics
  • 19. MEI Pharma, Inc.
  • 20. Merck & Co., Inc.
  • 21. Moleculin Biotech, Inc.
  • 22. NovalGen Ltd.
  • 23. Novartis AG
  • 24. Oncoternal
  • 25. Pfizer Inc.
  • 26. Prelude Therapeutics Incorporated
  • 27. Reverie Labs Inc.
  • 28. Sanofi S.A.
  • 29. Takeda Pharmaceutical Company Limited
  • 30. TG Therapeutics, Inc.
  • 31. Tvardi Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. HEMATOLOGICAL MALIGNANCIES MARKET RESEARCH PROCESS
  • FIGURE 2. HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. HEMATOLOGICAL MALIGNANCIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. HEMATOLOGICAL MALIGNANCIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HEMATOLOGICAL MALIGNANCIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HEMATOLOGICAL MALIGNANCIES MARKET DYNAMICS
  • TABLE 7. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BONE MARROW TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TYPES, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM HEMATOLOGICAL MALIGNANCIES MARKET SIZE, BY END-USERS, 2018-2030 (USD MILLION)
  • TABLE 193. HEMATOLOGICAL MALIGNANCIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. HEMATOLOGICAL MALIGNANCIES MARKET, FPNV POSITIONING MATRIX, 2023